Insider Transactions

What Zymeworks Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

	3 months	12 months
Open-market buys	0	0
Sells	1	11
Total trades	2	24

Shares traded

	3 months	12 months
Acquired	37,037	426,935
Disposed	13,832	201,765
Net activity	+23,205	+225,170

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

All Buys Sells

Insider	Relation	Date	Transaction	Shares	Price	Value	Shares held
Schayowitz Adam	EVP, Head of R&D	Oct 09	Open-market sale · S	−13,832	$25.85	−$358K	23,205
Schayowitz Adam	EVP, Head of R&D	Oct 09	Exercise / conversion · M	+37,037	—	—	37,037
Hollywood Mark	EVP & Chief Operating Officer	Jul 06	Grant / award · A	+939	$22.22	+$20.9K	133,852
Hollywood Mark	EVP & Chief Operating Officer	Jan 12	Open-market sale · S	−6,120	$22.67	−$139K	132,913
Hollywood Mark	EVP & Chief Operating Officer	Jan 12	Exercise / conversion · M	+17,666	—	—	139,033
Moore Paul Andrew	Chief Scientific Officer	Jan 12	Open-market sale · S	−9,560	$22.67	−$217K	48,497
Moore Paul Andrew	Chief Scientific Officer	Jan 12	Exercise / conversion · M	+17,666	—	—	58,057
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12	Open-market sale · S	−9,310	$22.67	−$211K	26,708
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12	Exercise / conversion · M	+17,666	—	—	36,018
Galbraith Kenneth	Chair & CEO	Jan 12	Open-market sale · S	−30,424	$22.67	−$690K	226,842
Galbraith Kenneth	Chair & CEO	Jan 12	Exercise / conversion · M	+64,000	—	—	257,266
Patterson Leone D	EVP, Chief Bus & Fin Officer	Jan 06	Grant / award · A	+459	$10.55	+$4.84K	459
Moore Paul Andrew	Chief Scientific Officer	Jan 05	Open-market sale · S	−10,821	$25.10	−$272K	40,391
Moore Paul Andrew	Chief Scientific Officer	Jan 05	Exercise / conversion · M	+20,000	—	—	51,212
Moore Paul Andrew	Chief Scientific Officer	Jan 05	Open-market sale · S	−9,289	$25.10	−$233K	31,212
Moore Paul Andrew	Chief Scientific Officer	Jan 05	Exercise / conversion · M	+17,168	—	—	40,501
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05	Open-market sale · S	−10,538	$25.10	−$264K	18,352
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05	Exercise / conversion · M	+20,000	—	—	28,890
Galbraith Kenneth	Chair & CEO	Jan 05	Open-market sale · S	−31,686	$25.10	−$795K	193,266
Galbraith Kenneth	Chair & CEO	Jan 05	Exercise / conversion · M	+66,666	—	—	224,952

Page 1 of 6 · showing the 20 most recent Sign up free to view all 101 transactions and filter by insider →

Comments